On May 10, 2022 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported business highlights and financial results for the first quarter ended March 31, 2022 (Press release, Delcath Systems, MAY 10, 2022, View Source [SID1234614102]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Recent Business Highlights
During and since the first quarter, Delcath:
Held a pre-NDA meeting with FDA and announced plans to file an NDA in the third quarter of 2022,
Announced the acceptance of a poster presentation updating results from the FOCUS Phase 3 Trial at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2022 Annual Meeting,
Resumed direct responsibility for sales, marketing, and distribution activities for the CHEMOSAT Hepatic Delivery System in all of Europe,
Achieved medical device regulation (MDR) certification for CHEMOSAT in Europe, which is now regulated as a Class lll device,
Announced that investigators from the University Hospital Southampton published in Melanoma Research results of a single center study on Delcath’s CHEMOSAT Hepatic Delivery System in 81 metastatic uveal melanoma patients with liver dominant disease receiving 250 treatments showing hepatic disease control rate of 88.9%, hepatic response rate of 66.7% and overall response rate of 60.5%, and
Appointed David Hoffman as General Counsel and Chief Compliance Officer and Anthony Dias as Vice President of Finance.
"During and since the first quarter, we held a pre-NDA meeting with FDA and, while we wait for the final meeting minutes from FDA, we do not believe any additional pre-clinical or clinical studies will be required in order to file the NDA. We expect to file the NDA in the third quarter of 2022," said Gerard Michel, CEO of Delcath. "Additionally, the body of published research on the efficacy of our CHEMOSAT system in the European commercial setting continued to grow, we resumed direct sales of CHEMOSAT in Europe, and we strengthened our leadership team. These accomplishments move us much closer to achieving our strategic priorities — filing of the HEPZATO NDA, preparing for the subsequent US launch when approved, and expanding the clinical development of HEPZATO and CHEMOSAT into additional indications of high unmet medical need."
First Quarter 2022 Results
Income Statement Highlights.
Total revenue for the three months ended March 31, 2022 and 2021, was approximately $0.3 million, from primarily sales of CHEMOSAT in Europe. Research and development expenses for the quarter were $4.2 million compared to $3.7 million in the prior year quarter. Selling, general and administrative expenses for the quarter were approximately $3.6 million compared to $3.3 million in the prior year quarter. Total operating expenses for the quarter were $7.9 million compared with $7.0 million in the prior year quarter.
The Company recorded a net loss for the three months ended March 31, 2022, of $8.2 million, compared to a net loss of $6.7 million for the same period in 2021.
Balance Sheet Highlights
On March 31, 2022, the Company had cash, cash equivalents and restricted cash totaling $20.5 million, as compared to cash, cash equivalents and restricted cash totaling $27.0 million on December 31, 2021. During the three months ended March 31, 2022, and March 31, 2021, we used $6.4 million and $4.6 million, respectively, of cash in our operating activities.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.